KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety,
tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with
HCC.